Updates
Showing
Technology and Climate change
Key points The transition to green energy may reduce the cost of energy as renewable energy becomes cheaper than fossil fuels for most applications. Cheaper energy will support future technology. The environmental impact of technologies such as a...
Hydrogen – an explosive gas or the future of green energy?
The European Patent Office (EPO) and International Energy Agency (IEA) have co-authored a report on patenting technology related to hydrogen. Here, Tim Belcher, partner in EIP’s Elements team, digests aspects of the report relating to storage and...
Vernacare Limited v Moulded Fibre Products Limited [2022] EWHC 2197 (IPEC)
Background The Claimant, Vernacare Limited (“Vernacare”), and the Defendant, Moulded Fibre Products Limited (“MFP”), both manufacture and sell washbowls, which are made from moulded paper pulp as used in hospitals, care homes a...
Intellectual property key UK strength in global semiconductor supply chain – Select Committee Report
A group of influential MPs from the Business, Energy and Industrial Strategy (BEIS)Select Committee has released its Report on the semiconductor industry in the UK. The Committee took evidence from various industry representatives over the summer and i...
Changes in the semiconductor industry: how patent strategies need to adapt
Introduction Nobody can deny that the semiconductor industry is going through something of a renaissance period. Semiconductors are firmly in the public eye thanks mainly to the ongoing chip shortages which have disrupted everything from car production...
The Concept of “Technical Character” becomes increasingly relevant for healthcare patents – Lessons from Recent EPO BoA Decisions
As patent attorneys practicing in the healthcare sector, we are encountering more and more inventions which straddle the life and computer science fields. AI and smart technologies are now a central feature in many medical technologies. In claims inco...
Patents Court affirms power to grant injunctions for pre-grant patents, but refuses injunction for Novartis
Swiss drug-maker, Novartis, sought a preliminary injunction to keep Teva and four other generics off the market for its prescription-only relapse remitting multiple sclerosis treatment, fingolimod, sold under the brand name “Gilenya”. The P...
G1/22 & G2/22: Entitlement to priority
Background As shown by the figure above, the applications in question are European stage of an application under the Patent Cooperation treaty (PCT) and its divisional applications. These applications claim priority from a priority application which li...